Ore­gon's Cas­cade Chem­istry looks to boost its Amer­i­can-made API pro­duc­tion with $14M in­vest­ment

Amid height­ened calls for Amer­i­can-made drugs, a suite of con­tract man­u­fac­tur­ers are mak­ing big in­vest­ments to boost sup­ply. Now, an Ore­gon CD­MO is step­ping up to the plate to grow its API con­tract busi­ness.

Cas­cade Chemisty will triple its to­tal floor space with a $14 mil­lion in­vest­ment, the com­pa­ny said in a press re­lease. Site con­struc­tion is al­ready un­der­way on a 28,000 square-foot build­ing, which will in­clude suites for Phase I and Phase II man­u­fac­tur­ing with flow hy­dro­gena­tion and re­ac­tors up to 400 liters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER